A randomised trial of oral prednisone for cystic fibrosis pulmonary exacerbation treatment
Valerie Waters(University of Toronto), Sanja Stanojevic(Dalhousie University), Bradley S. Quon(St. Paul's Hospital), Lara Bilodeau(Institut universitaire de cardiologie et de pneumologie de Québec), Patrick Daigneault(Centre hospitalier universitaire de Québec), Michelle Shaw(SickKids Foundation), Félix Ratjen(Hospital for Sick Children), Hartmut Grasemann(Hospital for Sick Children), Melanie Chin(Reata Pharmaceuticals (United States)), Sze Man Tse(Centre Hospitalier Universitaire Sainte-Justine), April Price(London Health Sciences Centre), Michael D. Parkins(University of Calgary), Annick Lavoie(Hotel Dieu Hospital), Melinda Solomon(Hospital for Sick Children), Jonathan H. Rayment(BC Children's Hospital), Elizabeth Tullis(St. Michael's Hospital), Julian S. Tam(University of Saskatchewan), Martha L. McKinney(Children's Hospital of Los Angeles), Michael Nicholson(London Health Sciences Centre), Lucy Perrem(Children's Health Ireland at Crumlin)
Cited by 13
Related Papers
Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del<i>CFTR</i>
|New England Journal of Medicine|2015|1.6k
Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
|New England Journal of Medicine|2013|990
The Effect of Chronic Infection With Aspergillus fumigatus on Lung Function and Hospitalization in Patients With Cystic Fibrosis
|CHEST Journal|2009|372
Executive Summary of the Second International Guidelines for the Diagnosis and Management of Pediatric Acute Respiratory Distress Syndrome (PALICC-2)
|Pediatric Critical Care Medicine|2023|297